Indian Authorized Agent for Medical Devices: Complete Guide for Foreign Manufacturers

Foreign manufacturers seeking to import and market medical devices in India must navigate the regulatory framework set by the Central Drugs Standard Control Organisation (CDSCO) under the Medical Devices Rules (MDR), 2017. A core requirement is the appointment of an Indian Authorized Agent (also called Authorised Agent or IAA). This local representative enables compliance, handles regulatory submissions, and serves as the official interface with Indian authorities. This guide explains the role, eligibility, responsibilities, appointment process, and practical considerations based on MDR 2017 and related CDSCO guidance.

What Is an Indian Authorized Agent?

Under Rule 3(f) of the Medical Devices Rules, 2017, an “authorised agent” means a person including any firm or organisation who has been appointed by an overseas manufacturer through a power of attorney to undertake import of medical device in India.

Foreign manufacturers without a registered Indian subsidiary or legal entity cannot apply directly to CDSCO for an import licence. All applications for import licences (typically via Form MD-14 leading to Form MD-15) must be filed by the authorised agent on the manufacturer’s behalf. The agent holds the import licence and assumes defined regulatory responsibilities in India. This applies across device risk classes (A, B, C, and D) and covers both medical devices and in-vitro diagnostic devices regulated under the Rules.

Why Foreign Manufacturers Need an Authorised Agent

India’s regulatory system requires a local point of accountability for imported devices. The authorised agent ensures that documentation meets Indian requirements, manages communication with CDSCO (including responses to queries during review), and supports post-market obligations. Without a properly appointed agent holding the necessary local licences and a valid Power of Attorney, CDSCO will not process import licence applications. The agent’s name typically appears in regulatory records and related labelling or documentation contexts as required under the Rules.

Eligibility Requirements for an Indian Authorised Agent

To qualify, the entity must meet criteria aligned with MDR 2017 and CDSCO expectations:

• Be a resident of India or a corporation/enterprise established in India with a valid Corporate Identification Number (CIN).
• Hold a valid wholesale licence (Form 20B and 21B under the Drugs and Cosmetics Rules, 1945, or the corresponding Form MD-42 registration certificate under MDR 2017) or a manufacturing licence for medical devices.
• Maintain an active account on the CDSCO online portal (SUGAM / Online System for Medical Devices) for submissions.
• Receive a properly executed Power of Attorney (PoA) from the foreign manufacturer.

The PoA must authorise the agent specifically for import licence applications and related activities. It requires authentication—typically notarisation in the country of origin followed by apostille or legalisation through the Indian Embassy/Consulate, or authentication by a Magistrate of the First Class in India, consistent with the Fourth Schedule of MDR 2017. The agent must also provide an undertaking confirming compliance with the Rules.

Key Responsibilities of the Authorised Agent

The agent’s duties, drawn from the Rules and associated documentation requirements, include:

• Preparing and submitting the import licence application (Form MD-14) with supporting documents such as the Device Master File, Plant Master File, Free Sale Certificate, ISO 13485 certificate, and other technical information specified in the Fourth Schedule.
• Acting as the official liaison with CDSCO for queries, inspections, and clarifications during the review process.
• Holding the granted import licence (Form MD-15) and managing its retention (periodic fee payments as applicable).
• Handling post-approval changes, endorsements, and notifications (major changes generally require prior approval; minor changes and constitution changes must be notified within specified timelines, commonly 30 days).
• Supporting post-market surveillance, including adverse event/serious adverse event reporting within the timelines prescribed under the Rules, and coordinating recalls or corrective actions when required.
• Remaining responsible for devices already imported into India even after withdrawal of the Power of Attorney, in cases of violations of the Drugs and Cosmetics Act, 1940 or MDR 2017.

Importation logistics, distribution, and commercial activities may be handled by the agent or separate parties depending on the commercial agreement; the regulatory responsibilities listed above remain with the authorised agent.

Process of Appointing an Authorised Agent

1. Identify a qualified Indian entity that meets the licence and portal registration requirements and has relevant regulatory experience.
2. Execute a detailed Power of Attorney covering the scope of authorisation (import licence applications, communication with CDSCO, post-market obligations, etc.). Ensure proper authentication and apostille/legalisation.
3. The agent registers or uses its existing CDSCO portal account and submits the application with the PoA, undertaking, and technical dossier.
4. Maintain clear contractual terms covering confidentiality, data access, change notifications, liability allocation, and termination procedures.

Changing an authorised agent after licence grant is possible but operationally significant. It typically requires a fresh application process or specific notifications and can temporarily affect import continuity. Manufacturers should therefore select carefully and document the commercial and regulatory relationship thoroughly.

Practical Considerations for Foreign Manufacturers

Select an agent with demonstrated knowledge of MDR 2017 classifications, grouping principles, clinical evidence expectations (especially for higher-risk or novel devices), and experience navigating CDSCO queries. Verify the agent’s current wholesale or manufacturing licence status and portal access. Clarify whether the agent will also act as importer of record or whether separate importers will be used. Establish processes for timely sharing of technical updates, complaint data, and change information so the agent can meet notification deadlines.

The import licence remains subject to the conditions of MDR 2017, including quality management system conformity (Fifth Schedule), labelling requirements (Rule 44), residual shelf-life rules at import, and ongoing vigilance. Class A (non-sterile, non-measuring) devices may follow simplified registration pathways in certain cases, yet an authorised agent is still generally required for foreign manufacturers.

Conclusion

Appointing a competent Indian Authorised Agent is a mandatory and foundational step for foreign medical device manufacturers under the Medical Devices Rules, 2017. The agent bridges the regulatory gap between the overseas manufacturer and CDSCO, enables the import licence process, and carries ongoing compliance duties. Careful selection, a robust Power of Attorney, and clear ongoing collaboration help ensure smooth market access and sustained regulatory compliance in India.

At MDR Consultants we support foreign manufacturers with authorised agent services, dossier preparation, portal submissions, and full CDSCO registration guidance aligned with current MDR 2017 requirements. Contact our team for tailored assistance on your India market entry strategy.

Last Updated : 02 Sep 2026